Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Summit Therapeutics Inc. stands amongst them. Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical company focused on non-small cell lung cancer (NSCLC), has made significant strides with its lead investigational drug, ivonescimab. The HARMONi Phase III trial for EGFR-mutated NSCLC patients demonstrated a statistically significant improvement in progression-free survival when ivonescimab was combined ...